kpt-9274
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02702492)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NAMPT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- kpt-9274
- kpt-9274
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04914845 | Phase 1 | Aug 27, 2021 | Karyopharm Therapeutics Inc, University of Colorado, Denver |
| NCT04281420 | Phase 1 | Mar 31, 2020 | Antengene Corporation |
| NCT02702492 | Phase 1 | Jun 1, 2016 | Karyopharm Therapeutics Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | For profit | 2 | 1 | 1 | 2016 |
| Antengene Corporation | For profit | 1 | 1 | 1 | 2020 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1